Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 56 Florida 39 Texas 34 New York 29 Massachusetts 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC2 Cartography Biosciences1 Intuitive Surgical1 TiumBio Co., Ltd.1 Ono Pharmaceutical Co., Ltd.1
State
California56 Florida39 Texas34 New York29 Massachusetts22
All 38 states
Target enrolment
to

Trials with a site in Texas

34 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
GI Windows, Inc.
Not applicable
30
Florida, Texas
2026-04-01
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
Radiopharm Theranostics, Ltd
Phase 1/2
61
Alabama, Michigan, Nebraska, Texas
2026-02-23
Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
Blue Earth Diagnostics
Phase 1/2
71
Texas
2026-02-19
Recruiting
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
DrugsEnlituo·Zirabev·Erbitux·Avastin
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
DrugsTrastuzumab·Cetuximab
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
DrugIDOV-Immune
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
NCT06598007Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugFolfox
Crossignal Therapeutics, Inc.
Phase 1/2
78
Texas
2024-09-20
Active, closed
Rgenta Therapeutics Inc
Phase 1
105
Massachusetts, Michigan, New York, Texas, Virginia, Washington
2024-08-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
DrugLenvatinib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma
JSR Medical Co., Ltd.
Not applicable
256
New York, Pennsylvania, Texas
2023-12-04
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Recruiting
Phanes Therapeutics
Phase 1/2
350
California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas
2023-03-15
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
DrugsTU2218·Keytruda·Pembrolizumab
TiumBio Co., Ltd.
Phase 1/2
140
Texas, Washington
2023-03-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
California, Rhode Island, Texas
2022-08-04
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
302
Florida, Georgia, Illinois, New York, Pennsylvania, Tennessee, Texas, Washington
2021-06-25
Active, closed
da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures
NCT04403022Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors
Intuitive Surgical
Not applicable
60
Florida, Michigan, Minnesota, Nevada, Pennsylvania, Texas, Washington
2021-06-03
Active, closed
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
NCT04046445Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
DrugEzabenlimab
Amal Therapeutics
Phase 1
96
Arizona, California, Colorado, New York, North Carolina, Texas
2019-07-22
Active, closed
Toray Industries, Inc
Phase 1
138
Arizona, California, Louisiana, New Jersey, New York, Oregon, Texas, Virginia
2019-04-26
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

22 of the 34 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 34 studies
PhaseStudiesRecruitingShare
Phase 117850%
Phase 1/28723.5%
Phase 26517.6%
Not applicable328.8%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC21
Affini-T Therapeutics, Inc.10
Alentis Therapeutics AG11
Amal Therapeutics10
ArriVent BioPharma, Inc.11
Blue Earth Diagnostics11
Cartography Biosciences11
Clasp Therapeutics, Inc.10
Criterium, Inc.11
Crossignal Therapeutics, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.